Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) EBIT Margin (2022 - 2025)

Historic EBIT Margin for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to 14518.37%.

  • BioXcel Therapeutics' EBIT Margin fell 73721100.0% to 14518.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 6738.3%, marking a year-over-year decrease of 33715600.0%. This contributed to the annual value of 2967.56% for FY2024, which is 94804100.0% up from last year.
  • According to the latest figures from Q3 2025, BioXcel Therapeutics' EBIT Margin is 14518.37%, which was down 73721100.0% from 13210.0% recorded in Q2 2025.
  • In the past 5 years, BioXcel Therapeutics' EBIT Margin ranged from a high of 449714.29% in Q1 2022 and a low of 28459.85% during Q3 2022
  • Moreover, its 4-year median value for EBIT Margin was 7146.26% (2024), whereas its average is 19738.34%.
  • Per our database at Business Quant, BioXcel Therapeutics' EBIT Margin crashed by 2000000000bps in 2023 and then soared by 207016800bps in 2024.
  • Over the past 4 years, BioXcel Therapeutics' EBIT Margin (Quarter) stood at 22224.37% in 2022, then soared by 76bps to 5285.9% in 2023, then skyrocketed by 46bps to 2866.94% in 2024, then tumbled by -406bps to 14518.37% in 2025.
  • Its EBIT Margin stands at 14518.37% for Q3 2025, versus 13210.0% for Q2 2025 and 6011.31% for Q1 2025.